Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PEG 400
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02260076

Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Telmisartan/Amlodipine
Drug: Amlodipine

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 84

Registration Number: NCT02259829

Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity

Phase 1

Completed

Conditions: Spinal Cord Injuries

Interventions: Drug: Placebo
Drug: KUC 7483 CL

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT02259751

Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/amlodipine fixed-dose combination tablet
Drug: Telmisartan
Drug: Amlodipine

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02259790

Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BEA 2180 BR infusion
Drug: BEA 2180 BR oral

First Posted Date: 2014-10-08

Last Posted Date: 2014-10-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02258971

Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILB 1941 ZW - single rising dose part
Drug: Placebo
Drug: BILB 1941 ZW - tablet
Drug: BILB 1941 ZW - solution
Other: standardized breakfast

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02256787

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBP 5371 CL tablet low dose
Drug: BIBP 5371 CL tablet high dose
Drug: Placebo drinking solution
Drug: BIBP 5371 CL solution
Other: High fat, high caloric breakfast
Drug: BIBP 5371 CL tablet
Drug: Placebo tablet

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT02256709

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment B
Drug: Treatment C
Drug: Placebo
Drug: Treatment A
Drug: Treatment D
Drug: Moxifloxacin

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT02256735

In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: KUC 7483 CL
Drug: Salmeterol
Drug: Acipimox
Drug: Bisoprolol
Drug: Propranolol

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02256722

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIRT 2584 XX
Drug: Warfarin sodium
Drug: Omeprazole
Drug: Dextromethorphan hydrobromide
Drug: Caffeine
Drug: Midazolam hydrochloride
Drug: Vitamin K1

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02256813

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy